STOCK TITAN

Instil Bio Reports Third Quarter 2026 Financial Results and Provides Corporate Update

(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Tags

Instil Bio (TIL) reported a third-quarter 2026 net loss of $4.2 million, narrowing from the corrected year-earlier loss. Loss per share was $0.62 versus $2.01, while nine-month net loss narrowed to $13.0 million from $63.5 million. Quarterly research and development expenses fell to $0.2 million from $9.1 million; general and administrative expenses declined to $5.8 million from $6.3 million.

Cash, restricted cash and investments totaled $67.1 million at September 30, 2026, versus $76.3 million at December 31, 2025. Instil expects these resources to fund its operating plan through 2027 and plans to build asset-focused subsidiaries through internal development or licensing. Prior-period figures were corrected for property-tax, tenant-reimbursement presentation and other immaterial errors; no prior filing is being amended.

Loading...
Loading translation...
14 points · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

0 major · 8 points

Hollow bars mark forward-looking points. How the balance works

Positive

  • Moderate pointThird-quarter net loss narrowed to $4.231 million, or $0.62 per share, from $13.587 million, or $2.01, year over year.
  • Moderate point. Forward-looking: it has not happened yet and may not happen.Instil expects September 30, 2026 cash and investments to fund its operating plan through 2027.
  • Minor pointNine-month net loss narrowed to $13.023 million, or $1.92 per share, from $63.495 million, or $9.58, year over year.
  • Minor point. Forward-looking: it has not happened yet and may not happen.Instil plans asset-focused development subsidiaries, building candidates through internal development or licensing.
  • Minor pointThird-quarter research and development expenses fell to $233,000 from $9.127 million year over year.
9 minor points
  • Minor pointNine-month research and development expenses fell to $1.172 million from $21.241 million year over year.
  • Minor pointNine-month in-process research and development expenses fell to nil from $10 million year over year.
  • Minor pointThird-quarter general and administrative expenses declined to $5.833 million from $6.344 million year over year.
  • Minor pointNine-month general and administrative expenses declined to $17.510 million from $22.689 million year over year.
  • Minor pointThird-quarter restructuring and impairment costs became an $81,000 reversal, versus nil a year earlier.
  • Minor pointNine-month restructuring and impairment charges declined to $1.092 million from $16.622 million year over year.
  • Minor pointNine-month contract termination gain was $1.620 million, versus none a year earlier.
  • Minor pointThird-quarter interest expense declined to $1.554 million from $1.582 million year over year.
  • Minor pointRental income rose to $2.697 million quarterly and $8.090 million year-to-date, from $2.691 million and $8.076 million.

Negative

  • Moderate pointCash, restricted cash and investments declined to $67.091 million at September 30, 2026, from $76.295 million at year-end 2025.
  • Minor pointStockholders’ equity declined to $102.564 million at September 30, 2026, from $112.671 million at year-end 2025.
  • Minor pointTotal liabilities increased to $93.081 million at September 30, 2026, from $91.844 million at year-end 2025.
  • Minor pointTotal assets declined to $195.645 million at September 30, 2026, from $204.515 million at year-end 2025.
  • Minor pointThird-quarter interest income fell to $615,000 from $893,000 year over year.
3 minor points
  • Minor pointNine-month interest income fell to $1.925 million from $3.112 million year over year.
  • Minor pointNine-month interest expense increased to $4.688 million from $4.398 million year over year.
  • Minor pointNine-month other income of $267,000 became other expense of $196,000 year over year.

Key Figures

Cash and investments: $67.1 million Net loss: $4.2 million vs. $13.6 million Net loss: $13.0 million vs. $63.5 million +2 more
Cash and investments
$67.1 million
As of September 30, 2026; expected to fund the current operating plan through 2027
Net loss
$4.2 million vs. $13.6 million
Three months ended September 30, 2026 vs. 2025; 2025 amount as corrected
Net loss
$13.0 million vs. $63.5 million
Nine months ended September 30, 2026 vs. 2025; 2025 amount as corrected
Net loss per share
$0.62 vs. $2.01
Basic and diluted, three months ended September 30, 2026 vs. 2025; 2025 amount as corrected
Non-GAAP net loss per share
$0.48 vs. $1.75
Basic and diluted, three months ended September 30, 2026 vs. 2025; 2025 amount as corrected

Previous Earnings Reports

1 past event · Latest: Aug 13
Same Type 1 event
  1. Aug 13

    Q2 earnings

    24h Move
    +1.5%

    Q2 loss narrowed and expenses fell; cash resources were expected to fund operations beyond 2027.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

gaap, non-gaap net loss per share, marketable securities, stock-based compensation
4 terms
gaap financial
"U.S. generally accepted accounting principles (“GAAP”)."
GAAP, or Generally Accepted Accounting Principles, are a set of standardized rules and guidelines that companies follow when preparing their financial statements. They ensure consistency, transparency, and comparability across different companies, making it easier for investors to understand and compare financial information accurately. This helps investors make informed decisions based on trustworthy and uniform financial reports.
View in glossary
non-gaap net loss per share financial
"These non-GAAP financial measures include non-GAAP net loss and non-GAAP net loss per share"
Net loss per share calculated after changing the company’s GAAP net loss to exclude or modify certain items (for example, one-time charges, stock-based compensation, noncash impairment, restructuring costs, or other specified adjustments) and then dividing that adjusted loss by the company’s weighted-average shares outstanding. Companies choose which items to remove or alter when they present this non-GAAP measure, so the exact adjustments and whether the per-share figure uses basic or diluted shares must be disclosed; because those choices are not standardized, non-GAAP net loss per share can differ between companies and reporting periods.
marketable securities financial
"cash, cash equivalents, restricted cash, marketable securities and long-term investments"
Marketable securities are financial assets — such as publicly traded stocks, bonds, and short-term government bills — that a company can quickly sell for cash at a known price. Investors watch them because they show how much ready cash a company can access without selling core operations, like keeping money in a highly liquid savings account versus being tied up in a house, and they affect short-term risk, financial flexibility, and balance-sheet strength.
stock-based compensation financial
"excluding non-cash stock-based compensation expense and restructuring and impairment charges"
Stock-based compensation is when a company pays employees, directors or consultants with shares or the right to buy shares instead of or in addition to cash. It matters to investors because issuing stock or options spreads ownership thinner (like cutting a pie into more slices), which can reduce each existing share’s claim on profits and can also change reported earnings; investors watch it to assess true cost of running the business and how management is incentivized.
View in glossary

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

DALLAS, Nov. 16, 2026 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a biotechnology company building a portfolio of asset-focused subsidiaries to develop novel therapies for unmet medical needs, today reported its third quarter 2026 financial results and provided a corporate update.

Recent Highlights:

  • Asset-Focused Development Model: By combining focused and experienced teams with strategic support from Instil, Instil intends to establish a portfolio of asset-focused development subsidiaries. To accomplish this strategy, Instil intends to internally develop or in-license programs, building a diversified portfolio of development candidates.
  • Cash Position: Cash, cash equivalents, restricted cash, marketable securities and long-term investments totaled approximately $67.1 million as of September 30, 2026, which Instil expects will fund its current operating plan through 2027.

Third Quarter 2026 Financial and Operating Results:

As of September 30, 2026, Instil had cash, cash equivalents, restricted cash, marketable securities and long-term investments of $67.1 million, which consisted of $2.5 million in cash and cash equivalents, $0.4 million in restricted cash, $59.5 million in marketable securities and $4.6 million in long-term investments, compared to $76.3 million in cash, cash equivalents, restricted cash and marketable securities as of December 31, 2025, consisting of $6.6 million in cash and cash equivalents, $0.2 million in restricted cash and $69.5 million in marketable securities. Instil expects that its cash, cash equivalents, restricted cash, marketable securities and long-term investments as of September 30, 2026 will enable it to fund its operating plan through 2027.

In-process research and development expenses were nil for the three and nine months ended September 30, 2026, compared to nil and $10.0 million for the three and nine months ended September 30, 2025, respectively.

Research and development expenses were $0.2 million and $1.2 million for the three and nine months ended September 30, 2026, respectively, compared to $9.1 million and $21.2 million for the three and nine months ended September 30, 2025, respectively.

General and administrative expenses were $5.8 million and $17.5 million for the three and nine months ended September 30, 2026, respectively, compared to $6.3 million and $22.7 million, as corrected, for the three and nine months ended September 30, 2025, respectively.

 Restructuring and impairment charges, net were a reversal of costs of $0.1 million and a charge of $1.1 million for the three and nine months ended September 30, 2026, respectively, compared to nil and $16.6 million for the three and nine months ended September 30, 2025, respectively.

Net loss was $4.2 million and $13.0 million for the three and nine months ended September 30, 2026, respectively, compared to $13.6 million and $63.5 million, as corrected, for the three and nine months ended September 30, 2025, respectively. Net loss per share, basic and diluted, was $0.62 and $1.92 for the three and nine months ended September 30, 2026, respectively, compared to $2.01 and $9.58, as corrected, for the three and nine months ended September 30, 2025, respectively. Non-GAAP net loss per share, basic and diluted, was $0.48 and $1.32 for the three and nine months ended September 30, 2026, respectively, compared to $1.75 and $6.00, as corrected, for the three and nine months ended September 30, 2025, respectively; see the reconciliation of GAAP to non-GAAP measures below.

In preparing its third-quarter 2026 financial statements, Instil identified errors in previously issued financial statements relating to property taxes on its Tarzana, California facility and the presentation of amounts reimbursed by the facility’s tenant, as well as certain other immaterial errors. The errors were not material to any previously issued financial statements, and no prior filing is being amended. Instil has corrected the prior-period information in its Quarterly Report on Form 10-Q for the quarter ended September 30, 2026, and the 2025 amounts in this release are presented as corrected.

Note Regarding Use of Non-GAAP Financial Measures

In this press release, Instil has presented certain financial information that has not been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”). These non-GAAP financial measures include non-GAAP net loss and non-GAAP net loss per share, which are defined as net loss and net loss per share, respectively, excluding non-cash stock-based compensation expense and restructuring and impairment charges, net. Instil believes that these non-GAAP financial measures, when considered together with the GAAP figures, can enhance an overall understanding of Instil’s financial performance. The non-GAAP financial measures are included with the intent of providing investors with a more complete understanding of Instil’s operating results. In addition, these non-GAAP financial measures are among the indicators Instil’s management uses for planning purposes and to measure Instil’s performance. These non-GAAP financial measures should be considered in addition to, and not as a substitute for, or superior to, financial measures calculated in accordance with GAAP. The non-GAAP financial measures used by Instil may be calculated differently from, and therefore may not be comparable to, non-GAAP financial measures used by other companies. Please refer to the below reconciliation of these non-GAAP financial measures to the comparable GAAP financial measures.

About Instil Bio

Instil Bio, Inc. is a biotechnology company building a portfolio of asset-focused subsidiaries to develop novel therapies for unmet medical needs. For more information, visit www.instilbio.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “anticipates,” “believes,” “expects,” “exploring,” “evaluating,” “focused,” “future,” “intends,” “may,” “plans,” “potential,” “projects,” “targets,” and “will” or similar expressions are intended to identify forward-looking statements. Forward-looking statements include express or implied statements concerning Instil’s expectations regarding establishing a portfolio of asset-focused development subsidiaries, internally developing or in-licensing programs, and building a diversified portfolio of development candidates; Instil’s expectations regarding its capital position, resources, and balance sheet, including its cash runway; and other statements that are not historical fact. Forward-looking statements are based on management’s current expectations and are subject to various risks and uncertainties that could cause actual results to differ materially and adversely from those expressed or implied by such forward-looking statements, including risks and uncertainties related to pursuing potential transactions to acquire companies or equity interests therein or in-license product candidates, and the sufficiency of Instil’s cash resources, as well as interest rates, inflation and other macroeconomic factors which could materially and adversely affect Instil’s business and operations, and other risks and uncertainties affecting Instil’s plans and strategy, including those discussed in the section titled “Risk Factors” in Instil’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2026 to be filed with the SEC and Instil ’s Annual Report on Form 10-K for the year ended December 31, 2025 filed on March 27, 2026, as well as Instil’s other filings with the SEC. These forward-looking statements do not constitute guarantees of future performance, and you are cautioned not to place undue reliance on these forward-looking statements. These forward-looking statements speak only as the date hereof, and Instil disclaims any obligation to update these statements except as may be required by law.

Contacts:

Investor Relations:
1-972-499-3350
investorrelations@instilbio.com
www.instilbio.com

Media Relations:

Kimberly Ha
KKH Advisors
1-917-291-5744
kimberly.ha@kkhadvisors.com


INSTIL BIO, INC.
SELECTED FINANCIAL DATA
 
Selected Condensed Consolidated Balance Sheet Data
(Unaudited; in thousands)
 
 September 30, 2026 December 31, 2025
Cash, cash equivalents, restricted cash, marketable securities and long-term investments$67,091 $76,295
Total assets$195,645 $204,515
Total liabilities$93,081 $91,844
Total stockholders’ equity$102,564 $112,671
      


Condensed Consolidated Statements of Operations
(Unaudited; in thousands, except share and per share amounts)
 
 Three Months Ended Nine Months Ended
 September 30, September 30,
  2026   2025   2026   2025 
Operating expenses:       
In-process research and development$—  $—  $—  $10,000 
Research and development 233   9,127   1,172   21,241 
General and administrative 5,833   6,344   17,510   22,689 
Restructuring and impairment charges, net (81)  —   1,092   16,622 
Total operating expenses 5,985   15,471   19,774   70,552 
Loss from operations (5,985)  (15,471)  (19,774)  (70,552)
Interest income 615   893   1,925   3,112 
Interest expense (1,554)  (1,582)  (4,688)  (4,398)
Other rental income 2,697   2,691   8,090   8,076 
Gain on contract termination —   —   1,620   — 
Other (expense) income, net (4)  (118)  (196)  267 
Net loss$(4,231) $(13,587) $(13,023) $(63,495)
Net loss per share, basic and diluted$(0.62) $(2.01) $(1.92) $(9.58)
Weighted-average shares used in computing net loss per share, basic and diluted 6,781,976   6,757,742   6,781,976   6,629,949 
                


INSTIL BIO, INC.
Reconciliation of GAAP to Non-GAAP Net Loss and Net Loss per Share
(Unaudited; in thousands, except share and per share amounts)
 
 Three Months Ended Nine Months Ended
 September 30, September 30,
  2026   2025   2026   2025 
Net loss$(4,231) $(13,587) $(13,023) $(63,495)
Adjustments:       
Non-cash stock-based compensation expense 984   1,768   3,005   7,087 
Restructuring and impairment charges, net (81)  —   1,092   16,622 
Non-GAAP net loss$(3,328) $(11,819) $(8,926) $(39,786)
Net loss per share, basic and diluted$(0.62) $(2.01) $(1.92) $(9.58)
Adjustments:       
Non-cash stock-based compensation expense per share 0.15   0.26   0.44   1.07 
Restructuring and impairment charges, net per share (0.01)  —   0.16   2.51 
Non-GAAP net loss per share, basic and diluted*$(0.48) $(1.75) $(1.32) $(6.00)
Weighted-average shares outstanding, basic and diluted 6,781,976   6,757,742   6,781,976   6,629,949 

* Non-GAAP net loss per share, basic and diluted may not total due to rounding.


FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What were Instil Bio’s third-quarter 2026 earnings results?

Instil Bio reported a net loss of $4.231 million, or $0.62 per basic and diluted share, compared with a corrected loss of $13.587 million, or $2.01 per share, in the third quarter of 2025.

How long does Instil Bio expect its September 2026 cash and investments to last?

Instil Bio expects its September 30, 2026 cash, cash equivalents, restricted cash, marketable securities and long-term investments to fund its operating plan through 2027. These resources totaled approximately $67.1 million.

What does Instil Bio exclude from its non-GAAP loss figures?

Instil Bio excludes non-cash stock-based compensation and restructuring and impairment charges, net, from its non-GAAP loss measures. Third-quarter 2026 non-GAAP net loss was $3.328 million, or $0.48 per share, compared with $11.819 million, or $1.75 per share, a year earlier. These measures supplement rather than replace GAAP results.

Keep reading